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REVIEWSevere fever with thrombocytopenia syndrome: a newly discovered
emerging infectious diseaseD. X. Li
Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, ChinaAbstractSevere fever with thrombocytopenia syndrome (SFTS) is a newly discovered emerging infectious disease that has recently become epidemic in
Asia. The causative agent of SFTS is a novel phlebovirus in the family Bunyaviridae, designated SFTS virus (SFTSV). SFTS clinically presents with
high fever, thrombocytopenia, leukocytopenia, gastrointestinal disorders, and multi-organ dysfunction, with a high viral load and a high case-
fatality rate. In human infection, SFTSV targets microphages, replicates in the spleen of infected mice, and causes thrombocytopenia and a
cytokine storm. The tick disseminates virus to humans and animals, forming a special transmission model in nature. Person-to-person
transmission though direct contact with patient blood has been frequently reported. Measurements of viral RNA and antibodies have
been established for diagnosis, but vaccines and speciﬁc therapeutics are not available so far.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
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E-mail: lidx@chinacdc.cnIntroductionAn emerging infectious disease with an unknown agent was
noted in 2009 in China; its major characteristics are severe
fever, thrombocytopenia, leukocytopenia, gastrointestinal
symptoms, and a high case-fatality rate [1]. The disease has been
named severe fever with thrombocytopenia syndrome (SFTS)
[1–3]. A novel phlebovirus was isolated from acute patients,
ticks, and domestic animals, and was considered to be the
causal agent of the disease. The newly discovered virus was
named SFTS virus (SFTSV), and belongs to the genus Phlebovirus,
family Bunyaviridae [1–3]. Recently, conﬁrmed SFTS cases have
been reported from Japan and South Korea [4,5]. Another
novel phlebovirus, Heartland virus, was isolated in the USA
from two febrile patients with thrombocytopenia and leuko-
cytopenia [6].Microbiol Infect 2015; 21: 614–620
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.03.001VirologyThe causative agent of SFTS is SFTSV, which is a tick-borne
virus in the family Bunyaviridae, genus Phlebovirus. The ﬁrst
isolation of SFTSV was from an acute patient’s blood in 2010
[1,2]; more strains of SFTSV were isolated later in China, Japan,
and Korea [4,5,7,8]. Vero, Vero E6, DH82, L929, THP-1 and
U937 cells are susceptible to infection with SFTSV [1,9–11]. As
SFTSV is a newly identiﬁed member of the family Bunyaviridae,
its morphology is compatible with that of a bunyavirus. SFTS is a
spherical particle with a lipid bilayer envelope and a diameter of
~100 nm; it contains a tripartite single-stranded negative-sense
RNA genome [1,12,13]. The genome of SFTSV consists of three
segments, designated S (small, 1744 nucleotides), M (medium,
3378 nucleotides), and L (large, 6368 nucleotides), based on the
relative nucleotide lengths; it encodes the nucleocapsid protein
(N, 246 amino acids) and non-structural protein (NSs, 294
amino acids) by an ambisense strategy, glycoprotein precursor
(which eventually matures into the envelop glycoproteins Gn
and Gc, of 582 amino acids and 512 amino acids, respectively)
through one open reading frame, and viral RNA-dependent
RNA polymerase (2084 amino acids) through one openious Diseases. Published by Elsevier Ltd. All rights reserved
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located at the 30 and 50 termini. The most terminal nucleotide
sequences of each segment are highly conserved. Base-pairing
of the terminal nucleotides formed panhandle structures that
circular RNAs to stabilize viral RNA and originate viral repli-
cation [1,12,13]. Intragenic recombination and genomic
segment reassortment have been found in SFTSV [14–16].
SFTSV forms plaques in Vero cell culture, and the plaque
reduction neutralization test has been used to detect neutral-
izing antibody. The pseudovirus expressing SFTSV glycoproteins
expressed infects human lung, kidney, liver, colon, retinal
epithelium, and glioblastoma cell lines, as well as human
monocyte-derived dendritic cells, with high efﬁciency [11]. The
glycoproteins of SFTSV use the lectin DC-SIGN as a receptor
for host cell entry, and the entry is pH dependent [11,14].
SFTSV-infected human macrophage cell lines THP-1 and U937
showed that the viral nucleocapsid protein co-localized with
the Golgi apparatus, and was closely surrounded by endo-
plasmic reticulum in the perinuclear region, suggesting that the
Golgi complex and endoplasmic reticulum are probably the
sites for formation and maturation of SFTSV viral particles [10].
SFTSV proteins show 33%, 30–36%, 30–41% and 11–13%
similarity to either Rift Valley fever virus (RVFV) or Uukuniemi
virus (UUKV), RNA polymerase, glycoproteins, and N and NSsFIG. 1. Geographical distribution of SFTS in China.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyproteins, respectively. No putative NSm protein has been found
in the glycoprotein precursor. SFTSV sequences form a new
clade within the genus Phlebovirus [17].EpidemiologyFrom 2011 to 2014, >3500 SFTS cases were reported in China
(Fig. 1), with an average case-fatality rate of 7.8%; the case-
fatality rate varied between different regions and years (http://
www.cdpc.chinacdc.cn). The cases were distributed in 20
provinces of China. Japan and South Korea reported conﬁrmed
SFTS cases in 2013 [4,5]. A febrile patient from North Korea
working in Dubai presented with SFTS clinical features, but
without a laboratory diagnosis [18]. The earliest infection was
traced back to 2005 in Japan [4]. In China, the gender ratio of
SFTS was 0.94 (male/female); >86% patients were farmers
[1–3,13] (http://www.cdpc.chinacdc.cn), and most of them
livedin wooded and hilly regions for planting of grains or tea.
The age composition of SFTS patients varied widely, from 8
months to 93 years; 90.84% of patients were aged 40–79 years
(http://www.cdpc.chinacdc.cn). A broad seasonal distribution of
SFTS was obvious; cases arose from March, and ended around
November, with the peak of incidence being in May to July inand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 614–620
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matched tick, and not mosquito, activities in endemic areas [1].
Some SFTS patients had a history of being recently tick-bitten.
SFTSVs were detected and isolated from Haemaphysalis long-
icornis ticks, including those collected from grass, domestic
animals, and SFTS patients [1,8,21,22]. The nucleotide se-
quences of SFTSVs isolated from ticks showed high homology
with those of SFTVs from patients’ blood [8,23,24]. Two SFTSV
strains isolated from the ticks removed from the body and
blood of an SFTS patient showed 99.7% homology of nucleotide
sequences of M segments [24]. H. longicornis is distributed in at
least 21 provinces of China [25], and is the dominant species in
the endemic areas [26]. The above ﬁndings suggest that the tick
vector plays a major role in the SFTSV life cycle and SFTSV
transmission. The situation regarding SFTSV infection of sheep,
cattle, dogs, pigs and chicken has been investigated [8,19,22]. It
was conﬁrmed that SFTSV is circulating among several species
of domesticated animals, with high infection rates in endemic
areas of China. In Shandong province, SFTSV infection rates
(viral RNA or antibody positive) were as follows: 73.31% (346/
472) of sheep, 64.61% (544/842) of cattle, 43.18% (155/359) of
dogs, 5.7% (48/839) of pigs, 49.15% (259/527) of chickens [8].
No animal illness or death has been observed [8,22]. Like some
arboviruses, such as Venezuelan equine virus and Japanese en-
cephalitis virus, the domesticated animals may act as amplifying
hosts for SFTSV, and sheep may be the main hosts in this
process. SFTSV most likely circulated between ticks and sheep
and other vertebrates, and was transmitted to humans via tick
bites [1,13,27–29]. Theoretically, humans can be infected
through contact with viraemic animal blood. However, SFTSV
infection of domesticated animals results in only transient vir-
aemia, with a low virus load (1.7–2.0 × 104 viral gene copies/
mL) [8]. So far, no stockbreeding and slaughtering associated
professional infections of SFTS have been reported. Person-to-
person transmission of SFTSV has been demonstrated in China
[21,30–36]. Of all person-to-person transmission events, index
case was fatal with a high virus load in blood. A patient with
virus load of 3.55 × 1010 (viral gene copies/mL) in blood was
reported [32]. The dying and dead SFTS patients produced
blood or bloody secretions from the mouth, nose or vagina,
and person-to-person infection happened by contact with the
contaminants. The secondary cases were usually family mem-
bers, relatives, neighbours, medical care workers, and mortuary
beauticians [30–36]. All of the secondary cases came into
contact with SFTS patients’ blood or bloody secretions without
effective personal protection [19,29–31]. The risk assessment
revealed that direct contact with patients’ blood was the major
risk factor for person-to-person transmission of SFTSV; there is
no evidence suggesting that airborne and faecal–oral trans-
mission play a role in person-to-person transmission [32].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectPerson-to-person transmission of SFTSV was similar to that of
viral haemorrhagic fevers caused by Ebola virus, Marburg virus,
and Crimean–Congo haemorrhagic fever virus, and the viruses
causing South America haemorrhagic fevers.
The infection rates of healthy populations ranged from 0.44%
to 6.37%, as determined with recombinant NP-based ELISA to
detect antibodies [8,21,37,38]. This reﬂects the fact that latent
infection with SFTS varies widely between different endemic
regions.
Clinical manifestations, pathology, and
pathogenesisThe incubation period of SFTS remains unclear, because most
of the patients denied a history of tick bites or did not recall the
exact date of tick bites, patients have been tick bitten in 2
weeks. The limited information on person-to-person trans-
mission suggests that the incubation period of SFTS is 5–15
days, and on average 7–13 days [30–32]. Because the infection
route and dose of virus were different, the incubation period
for person-to-person transmission may not fully reﬂect that of
tick-bitten cases.
SFTS shows a spectrum of severity, from mild, through
multi-organ failure, disseminated intravascular coagulation
(DIC), and death. The basic clinical manifestations of SFTS are
high fever, thrombocytopenia, leukocytopenia, and gastroin-
testinal disorders; multi-organ failure and DIC occur in severe
cases [1,16,39–41]. The clinical course of SFTS can divided into
three overlapping stages: the fever stage, the multi-organ
dysfunction stage, and the convalescent stage (Fig. 2) During
the fever stage, patients experience 1 week of fever and acute
non-speciﬁc symptoms. The disease initially presents with an
abruptly raised temperature. At the same time, the patients
present non-speciﬁc manifestations, such as fatigue, headache,
myalgia, anorexia, nausea, vomiting, diarrhoea, abdominal pain,
lymphadenopathy, thrombocytopenia, and leukocytopenia. The
ﬁndings of platelet, white blood cell, coagulation, biochemical
and other laboratory tests are often abnormal, beginning later
in this phase. Serum levels of alanine aminotransferase, aspar-
tate aminotransferase, lactate dehydrogenase, creatinine kinase
and creatinine kinase-MB begin to increase. This is followed by
the multi-organ dysfunction stage; during this stage, liver and
muscle enzymes are signiﬁcantly elevated, notable proteinuria
and haemorrhage appear, and multi-organ failure and DIC
develop in patients with severe SFTS. The survivors enter the
convalescent stage, and all of the clinical signs, symptoms and
laboratory parameters gradually return to normal [39]. The
temperature of most SFTS cases usually exceeds 38°C, and this
elevation lasts for 7–10 days; in some patients, the feverious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 614–620
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FIG. 2. Clinical course of SFTS. CK,
creatinine kinase; CNS, central ner-
vous system; DIC, disseminated
intravascular coagulation; LDH,
lactate dehydrogenase; MOD, multi-
organ dysfunction; MOF, multi-organ
failure.
CMI Li Severe fever with thrombocytopenia syndrome 617continues for 2 weeks [39,40]. Over 70% of the patients have
high fever of >39°C [39,40]. Platelet counts and leukocyte
counts of some SFTS patients are reduced to <50 000/cm3 and
<4000/cm3, respectively [1,39–41]. The most common
lymphadenopathy comprises painful, swollen unilateral sub-
inguinal lymph nodes [1]. The central nervous system symp-
toms include apathy, lethargy, muscular tremor, and
convulsions [1,39,40]. Coma frequently occurs in the terminal
stage of the disease. Haemorrhagic manifestations consist of
petechiae, ecchymosis, injection site haematoma, gingival
bleeding, haematemesis, haematuria, and melena [1,39–41].
Haemorrhage in SFTS patients is not usually lethal, with the
exception of DIC-associated massive haemorrhage and vital
organ haemorrhage, such as pneumorrhagia. Serum levels of
alanine aminotransferase, aspartate aminotransferase and
lactate dehydrogenase are elevated [1,39–42]. No cytological
changes are seen in the bone marrow of SFTS patients, sug-
gesting that the thrombocytopenia and leukopenia of SFTS do
not result from damage to haematopoietic cells [43].
The levels of a broad spectrum of serum cytokines, including
interleukin (IL)-1RA, IL-6, IL-10, granulocyte colony-stimulating
factor, interferon (IFN)-r-induced protein 10, and monocyte
chemotactic protein-1, are elevated in the acute phase in SFTS
patients, and these cytokines are present in higher levels in fatal
cases than in non-fatal cases [16,44]. The numbers of CD69+ T-
cells, HLA-DR+ cells and CTLA4+ T-cells are elevated. HighClinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologySFTSV viral loads are associated with variations in platelet,
serum enzymes, and proinﬂammatory and anti-inﬂammatory
cytokines [44,45].
SFTSV NP was detected in the cytoplasm of blastic cells and
necrotic regions in the cortical area of lymph nodes. Severe
necrotizing lymphadenitis with massive necrosis, which
comprised nuclear debris and eosinophilic ghosts but not
granulocytes, was distributed throughout the cortical area; the
depletion of small lymphocytes, and severe inﬁltration of his-
tiocytes and immunoblasts, were observed in the lymph nodes
[4]. Two autopasy cases were reported in Japan, The patho-
gnomonic histological feature was necrotizing lymphadenitis of
systemic lymphoid tissue with SFTSV and viral RNA [46].
An infectious model of SFTS in C57/BL6 mice was estab-
lished, and the animals developed symptoms of thrombocyto-
penia and leukocytopenia. Viral RNA and histopathological
changes were identiﬁed in the spleen, liver, and kidney. More-
over, the numbers of macrophages and platelets were signiﬁ-
cantly increased in the spleen, and SFTSV co-localized with
platelets in the cytoplasm of macrophages in the red pulp.
In vitro assays further revealed that SFTSV adhered to platelets
and facilitated the phagocytosis of platelets by mouse macro-
phages. Both of these ﬁndings suggest that the host splenic
macrophage clearance of virus-bound platelets reduced the
number of circulating platelets, causing thrombocytopenia [47].
Lethal infection was induced in α/β-IFN receptor knockoutand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 614–620
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inoculation of SFTSV. The virus antigen was found in the liver,
intestine, kidney, spleen, lymphoid tissue, and brain, but not in
the lungs [48]. In rhesus macaques, SFTSV causes fever,
thrombocytopenia, leukocytopenia and increased levels of
transaminases and myocardial enzymes in blood, without se-
vere symptoms or death. IgG, IgM and neutralizing antibodies
against SFTSV were induced in infected macaques. Levels of the
cytokines IFN-γ, eotaxin, tumour necrosis factor-α and
macrophage inﬂammatory protein-1β were signiﬁcantly
elevated. Minor pathological lesions were observed in the liver
and kidney during the late stages of infection [49].
The NSs protein of some phleboviruses suppresses IFN and
INF-β promoter activities [50]. The SFTSV NSs protein also
plays a major role in immune evasion. NSs was found to be
associated with TANK-binding kinase 1, and may inhibit the
activation of downstream interferon regulatory factor and nu-
clear factor-κB signalling through this interaction [9]. The viral
NSs forms inclusion bodies in SFTSV-infected and SFTSV-
transfected cells. NSs was able to sequester IKK, interferon
regulatory factor 3 and RIG-I signalling proteins into inclusion
bodies or virus-induced cytoplasmic structures, resulting in
reduced IFN-β induction, suggesting a novel mechanism for
SFTSV evasion of innate immunity [51,52].Diagnosis and treatmentThe diagnosis of SFTS based on clinical manifestations has been
shown to be unreliable, and should be conﬁrmed by laboratory
tests, because the clinical syndrome of SFTS can be confused
with Hemorrhagic Fever with Renal Syndrome and some
haematonoses.
Isolation of SFTSV is not difﬁcult, but usually takes 1–3
weeks, so virus isolation is not routinely performed for SFTS
diagnosis [1,4,5].
Taqman qPCR assays have been established to detect L, M
and S segments of SFTSV in the acute-phase serum of patients;
the assay sensitivities for sera collected 2–10 days and 11–20
days after the onset of symptoms were 100% and 93.8%,
respectively [53]. The S segment-based Taqman qPCR has been
licensed in China [53]. The sensitivity and speciﬁcity of the assay
are 98.6% and 99%, respectively, and the detection limit of the
assay is 100 copies/mL or 1 TCID50/mL [53]. A loop-mediated
isothermal ampliﬁcation assay targeting the S segment of SFTSV
has been developed; with this assay, the entire procedure was
completed within 30 min, and the sensitivity of the assay was
94.4% [54,55]. An RT-cross-priming ampliﬁcation with a ver-
tical ﬂow visualization strip assay based on the M segment of
SFTSV, with a sensitivity and speciﬁcity of 94.1% and 100.0%,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectrespectively, has been developed [56]. A multiplex real-time
RT-PCR assay has been developed for simultaneous detection
of SFTSV, Hantaan virus, Seoul virus and Dengue virus for pa-
tients 2–12 days after the onset of symptoms; the sensitivity
was 100% [57]. A qPCR detecting both the Chinese and Japa-
nese clades of SFTSV was established in Japan [58]. A puriﬁed
recombinant NP-based IgM capture ELISA, an indirect ELISA, a
double-sandwich ELISA, an immunochromatography assay
[1,8,58,59] and an immunoﬂuorescence assay (IFA) were
developed and optimized to determine virus-speciﬁc IgM, IgG
and total antibodies in sera of human and animals, and used for
SFTS diagnosis and surveillance. Indirect IFAs were also estab-
lished to determine virus-speciﬁc antibodies. The results of an
ELISA-based method (microtitre) to titre SFTSV were consis-
tent with those obtained by IFA (R = 0.99) and plaque-forming
(R = 0.95) methods [60]. Neutralizing antibody was determined
with a plaque reduction neutralization test and a microtitre-
based microneutralization assay.
Multiplex detection of viral haemorrhagic fevers, including
SFTS, were developed by means of the Luminex technique to
detect viral RNAs or antigens [61,62]. The SFTS patient’s sera
were tested by real-time PCR; 64.3% of the patients were viral
RNA positive during the ﬁrst week after onset, and 37.5% were
RNA positive during the second week [63]. Other studies
indicated that the viral RNA-positive rates of the patients were
60% (81/135) and 60.61% (20/33) [64,65].
So far, there is no speciﬁc treatment for SFTS; supportive
and symptomatic treatments are applied routinely. Ribavirin has
been used to treat haemorrhagic fevers caused by arenaviruses
and bunyaviruses [66,67]. In vitro, ribavirin inhibits SFTS repli-
cation in cell culture [2,68]. The effectiveness of ribavirin in
treating SFTS cases was investigated in a cross-sectional study,
but there were no signiﬁcant differences in case fatality rate,
platelet counts and viral load between patients who received
ribavirin and those who did not [42,69]. During the acute phase
of infection, the serum levels of multiple proinﬂammatory cy-
tokines were abnormal in patients with SFTS; plasma exchange
may decrease the cytokine imbalance. Two severe cases of
SFTS were successfully treated with plasma exchange and
ribavirin in South Korea.
It is difﬁcult to prevent or control SFTS infection in animals
and ticks, as the tick–animal–tick cycle usually goes unnoticed,
and the infection in domestic animals is usually not apparent.
The development of cell culture-based inactivated SFTS vac-
cines is in progress in China.Transparency declarationThe author declares that there is no conﬂicts of interest.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 614–620
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